Drug intelligence / Profile preview

cetuximab + enzastaurin + irinotecan

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of cetuximab (an EGFR inhibitor monoclonal antibody), enzastaurin (a protein kinase C inhibitor), and irinotecan (a topoisomerase I inhibitor). This regimen combines targeted therapy with chemotherapy to treat advanced cancers, particularly colorectal cancer. Cetuximab blocks EGFR signaling, enzastaurin inhibits PKC pathways, and irinotecan causes DNA damage by inhibiting topoisomerase I.

Brand names: Erbitux

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)TOP1 (DNA Topoisomerase I)PRKCB (Protein kinase C beta)

Beyond the preview

Go deeper on cetuximab + enzastaurin + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cetuximab + enzastaurin + irinotecan.

Explore the full profile